Transcatheter Tricuspid Valve Interventions: Midterm Results from the TriValve Registry

Transcatheter tricuspid valve intervention (TTVI) with various technologies is associated with lower mortality and clinical improvement, a new analysis of the TriValve Registry indicates.

The researchers, publishing in JACC Interventions, looked at mid-term data from the TriValve Registry, which included 312 high-risk patients with severe tricuspid regurgitation. Interventions, using a variety of technologies, targeted the leaflets, annulus, or coaptation and replacement. Implanted devices included the MitraClip, Trialign, TriCinch firs generation, caval valve implantation, FORMA, Cardioband, NaviGate, and PASCAL. Outcomes were determined prospectively at mid-term follow-up.

Procedural success was 72.8%. TTVI was performed as a stand-along procedure in 64% of cases. Mortality at 30 days was 3.6% and was lower in patients with procedural success (1.9% versus 6.9%; P=0.04). The results also suggested greater coaptation depth was an independent predictor of reduced device success (P=0.002). Actuarial survival at 1.5 years was higher in patients with procedural success.

“TTVI is feasible with different technologies, has a reasonable overall procedural success rate, and is associated with low mortality and significant clinical improvement. Mid-term survival is favorable in this high-risk population,” the study authors wrote. “Greater coaptation depth is associated with reduced procedural success, which is an independent predictor of mortality.”

Source: JACC Interventions